Monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) w/ activating mutations of epidermal growth factor receptor tyrosine kinase (EGFR-TK).
View Iressa overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Disperse tab in ½ glass of non-carbonated drinking water & stir w/o crushing then, drink immediately. Rinse glass w/ ½ glass of water & drink. Mixt may also be given via a nasogastric tube.
Perform EGFR mutation assessment prior to treatment. Interstitial lung disease; worsening of resp symptoms. Liver function test abnormalities. GI perforation. Concomitant use w/ CYP3A4 inducers; drugs that cause significant sustained elevation in gastric pH; warfarin; vinorelbine. Patients presenting w/ signs & symptoms suggestive of keratitis should be referred promptly to ophth specialist. Moderate to severe hepatic impairment (Child-Pugh B or C) due to cirrhosis; CrCl ≤20 mL/min; known CYP2D6 poor metaboliser. May impair ability to drive & use machines. Pregnancy & lactation.
Sign Out
